Abstract:Background: Although EGFR inhibitors (EGFRi), preferably osimertinib, have offered substantial benefit for the classical plus T790M EGFR-mutant NSCLC patients, drug resistance develops and poses a critical challenge for long-term survival. The resistance is rooted to either on-target secondary EGFR mutations or compensatory oncogenic pathways bypassing EGFRi intervention, one of which appears to be treatment-acquired MET amplification (METamp). In this study we set out to understand the conditions when the tumor cells become dependent on MET. Methods: NSCLC patient-derived tumor models (PDX) carrying classical and T790M EGFR driver mutations were selected based on EGFRi history and concurrent MET gene copy numbers or RNA expression levels: Type 1) resistant to osimertinib with METamp; Type 2) partially resistant to osimertinib with METamp; and Type 3) sensitive to osimertinib with low MET expression, no METamp. These PDX xenograft mice were treated with vebreltinib (APL-101) at clinically relevant doses as single agent or in combination with osimertinib. The pharmacodynamic effects on EGFR and MET phosphor (P)- and total proteins were analyzed from tumor samples harvested during and at the end of treatments. Results: Vebreltinib single agent inhibited tumor growth of the type-1 PDX. One such PDX was resistant to chemotherapies, BRAF inhibitor and EGFRi including osimertinib, was inhibited by vebreltinib with ED50 of 3 mg/kg (p.o/q.d.). Another such PDX tumor appeared to be eradicated by vebreltinib treatment at 10 mg/kg (p.o/q.d.) and the mice became tumor-free on Day 18 and remained so after dosing stop on day 21 with last observation at study end (Day 70). In comparison, reference METi savolitinib showed only partial tumor size reduction against the same PDX tumor, not as durable as vebreltinib, and did not eradicate tumor growth at the same dose as vebreltinib or in combo with Osimertinib. Re-grown tumor after savolitinib osimertinib combo dosing stop was inhibited completely by vebreltinib follow-on treatment. In the type-2 PDX, tumor growth was partially inhibited by vebreltinib but was completely inhibited by combo of vebreltinib and osimertinib. The anti-tumor activity of vebreltinib in type-1 and type-2 PDX was associated with pharmacodynamic inhibition of P-MET and P-EGFR and MET protein degradation. In the type-3 PDX, tumor growth appeared to be eradicated by osimertinib and not inhibited by vebreltinib. However, addition of vebreltinib suppressed tumor re-growth after osimertinib dosing stop. Conclusion: EGFR-mutant NSCLC resistance to EGFRi may be dependent on MET pathway regardless of acquired METamp, whereas METamp may dictate the degree of MET dependence. Our data supports the hypothesis that adding vebreltinib to EGFRi overcome MET dependent resistance with durable effect or preventing MET dependent resistance to maximize therapeutic benefits. Citation Format: Xiaoling Zhang, Elaine Liu, Yan Song, Peony Yu, Sanjeev Redkar, Guo-Liang Yu. Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6500.

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

Synergistic Antitumor Effects of Cmet Inhibitor in Combination with Anti-Vegf in Colorectal Cancer Patient-Derived Xenograft Models

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

Mechanism and Treatment Associated with Resistance to EGFR-TKI

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Combined Targeting Of The Estrogen Receptor And The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects

Marsdenia Tenacissima Extract Overcomes Axl- and Met-mediated Erlotinib and Gefitinib Cross-Resistance in Non-Small Cell Lung Cancer Cells

Clinical Efficacy Of Egfr-Tkis In Combination With Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer Harboring Egfr Mutations

Abstract 6500: Dependence of EGFR-mutant NSCLC on MET as demonstrated by vebreltinib, a novel and selective brain-penetrating MET kinase inhibitor

Efficacy of Epidermal Growth Factor Receptor Inhibitors in Combination with Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

EGFR TKIs Combinding the Inhibition of RAS-ERK Signaling in NSCLC Treatment

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC